Want to see CVKD full AI Analyst Report?
CVKD Stock Chart & Stats
$2.04
-$0.06(-2.94%)
At close: 4:00 PM EDT
$2.04
-$0.06(-2.94%)
Day’s Range― - ―
52-Week Range$1.86 - $14.64
Previous CloseN/A
Volume28.12K
Average Volume (3M)57.36K
Market Cap
$6.23M
Enterprise Value$10.02
Total Cash (Recent Filing)$2.31M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Aug 06, 2026EPS Estimate
-1.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.63
Shares Outstanding3,098,592
10 Day Avg. Volume57,981
30 Day Avg. Volume57,363
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)4.94
Price to Sales (P/S)0.00
P/FCF Ratio-1.07
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$29.00Price Target Upside1321.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-5.25
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory De‑risking: FDA‑guided Phase 3 For CAD‑1005Clear FDA guidance on a pivotal Phase 3 trial materially reduces clinical and regulatory uncertainty for CAD‑1005. A well‑defined path to a potential U.S. marketing application by 2029 strengthens the program’s development credibility and increases partner and investor interest over the next multi‑year horizon.
Shift To Franchise/partnering StrategyFormalizing a franchise and pursuing partnerships reduces capital intensity and execution risk for late‑stage assets. This structural move makes assets more scalable via external commercialization partners, improves chances of non‑dilutive value capture, and aligns incentives for larger pharma collaborations.
Low Leverage / No DebtZero reported debt preserves financial flexibility and avoids interest obligations that could strain cash in a pre‑revenue biotech. With no leverage, management can prioritize partnering or staged financings, improving optionality for funding pivotal trials without fixed debt servicing burdens.
Bears Say
Pre‑revenue With Accelerating Cash BurnSustained negative operating and free cash flow without product revenues means the business relies on external financing to advance trials. Accelerating burn widens funding needs and can force strategic tradeoffs, delaying development or diluting existing shareholders over the medium term.
Shrinking Equity Base Increases Dilution RiskA rapidly eroding equity base signals cumulative losses have materially depleted shareholder capital, making future equity financings likelier. This structural weakening elevates dilution risk and can constrain negotiation leverage with partners or investors during critical development milestones.
Management Turnover Risks Clinical ContinuityDeparture of the CMO amid pivotal program advancement creates execution and regulatory continuity risk. Combined with recent CFO transitions, leadership changes can slow protocol finalization, regulatory interactions, or partnering discussions and could affect trial timelines and external confidence over several months.
Cadrenal Therapeutics, Inc. News
CVKD FAQ
What was Cadrenal Therapeutics, Inc.’s price range in the past 12 months?
Cadrenal Therapeutics, Inc. lowest stock price was $1.86 and its highest was $14.64 in the past 12 months.
What is Cadrenal Therapeutics, Inc.’s market cap?
Cadrenal Therapeutics, Inc.’s market cap is $6.23M.
When is Cadrenal Therapeutics, Inc.’s upcoming earnings report date?
Cadrenal Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were Cadrenal Therapeutics, Inc.’s earnings last quarter?
Cadrenal Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$1.04 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Cadrenal Therapeutics, Inc. overvalued?
According to Wall Street analysts Cadrenal Therapeutics, Inc.’s price is currently Undervalued.
Does Cadrenal Therapeutics, Inc. pay dividends?
Cadrenal Therapeutics, Inc. does not currently pay dividends.
What is Cadrenal Therapeutics, Inc.’s EPS estimate?
Cadrenal Therapeutics, Inc.’s EPS estimate is -1.42.
How many shares outstanding does Cadrenal Therapeutics, Inc. have?
Cadrenal Therapeutics, Inc. has 3,098,592 shares outstanding.
What happened to Cadrenal Therapeutics, Inc.’s price movement after its last earnings report?
Cadrenal Therapeutics, Inc. reported an EPS of -$1.04 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.431%.
Which hedge fund is a major shareholder of Cadrenal Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CVKD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
CVKD Stock 12 Month Forecast
Average Price Target
$29.00
▲(1321.57% Upside)
Technical Analysis
Daré Bioscience
―
Vyome Holdings
―
Collplant Holdings
―
Lunai Bioworks
―
Tao Synergies
―
Ownership Overview
9.64% Insiders
1.90% Mutual Funds
0.04% Other Institutional Investors
86.77% Public Companies and
Individual Investors